Institute of Medical Genetics, Medical University of Vienna, Währinger Strasse 10, A-1090 Vienna, Austria.
Praxis fur Humangenetik, Brünnlbadgasse 15, A-1090 Vienna, Austria.
Mutat Res. 2010 Oct;705(2):130-140. doi: 10.1016/j.mrrev.2010.06.003. Epub 2010 Jun 30.
The heavy metals mercury and lead are well-known and significant developmental neurotoxicants. This review summarizes the genetic factors that modify their toxicokinetics. Understanding toxicokinetics (uptake, biotransformation, distribution, and elimination processes) is a key precondition to understanding the individual health risks associated with exposure. We selected candidate susceptibility genes when evidence was available for (1) genes/proteins playing a significant role in mercury and lead toxicokinetics, (2) gene expression/protein activity being induced by these metals, and (3) mercury and lead toxicokinetics being affected by gene knockout/knockdown or (4) by functional gene polymorphisms. The genetic background is far better known for mercury than for lead toxicokinetics. Involved are genes encoding L-type amino acid transporters, organic anion transporters, glutathione (GSH)-related enzymes, metallothioneins, and transporters of the ABC family. Certain gene variants can influence mercury toxicokinetics, potentially explaining part of the variable susceptibility to mercury toxicity. Delta-aminolevulinic acid dehydratase (ALAD), vitamin D receptor (VDR) and hemochromatosis (HFE) gene variants are the only well-established susceptibility markers of lead toxicity in humans. Many gaps remain in our knowledge about the functional genomics of this issue. This calls for studies to detect functional gene polymorphisms related to mercury- and lead-associated disease phenotypes, to demonstrate the impact of functional polymorphisms and gene knockout/knockdown in relation to toxicity, to confirm the in vivo relevance of genetic variation, and to examine gene-gene interactions on the respective toxicokinetics. Another crucial aspect is knowledge on the maternal-fetal genetic background, which modulates fetal exposure to these neurotoxicants. To completely define the genetically susceptible risk groups, research is also needed on the genes/proteins involved in the toxicodynamics, i.e., in the mechanisms causing adverse effects in the brain. Studies relating the toxicogenetics to neurodevelopmental disorders are lacking (mercury) or very scarce (lead). Thus, the extent of variability in susceptibility to heavy metal-associated neurological outcomes is poorly characterized.
重金属汞和铅是众所周知的重要发育神经毒物。本综述总结了改变其毒代动力学的遗传因素。了解毒代动力学(摄取、生物转化、分布和消除过程)是理解与暴露相关的个体健康风险的关键前提。当有证据表明(1)基因/蛋白质在汞和铅毒代动力学中发挥重要作用,(2)这些金属诱导基因表达/蛋白质活性,(3)汞和铅毒代动力学受基因敲除/敲低或(4)功能基因多态性影响时,我们选择候选易感性基因。与铅毒代动力学相比,汞的遗传背景要了解得多。涉及编码 L 型氨基酸转运体、有机阴离子转运体、谷胱甘肽 (GSH) 相关酶、金属硫蛋白和 ABC 家族转运体的基因。某些基因变异可以影响汞的毒代动力学,这可能部分解释了对汞毒性的易感性差异。δ-氨基酮戊酸脱水酶 (ALAD)、维生素 D 受体 (VDR) 和血色病 (HFE) 基因变异是人类铅毒性唯一公认的易感性标志物。在这一问题的功能基因组学方面,我们的知识仍然存在许多空白。这需要进行研究以检测与汞和铅相关疾病表型相关的功能性基因多态性,证明功能多态性和基因敲除/敲低与毒性的关系,确认遗传变异的体内相关性,并研究基因-基因相互作用对各自的毒代动力学的影响。另一个关键方面是了解调节胎儿暴露于这些神经毒物的母体-胎儿遗传背景的知识。为了完全确定具有遗传易感性的风险群体,还需要研究参与毒动学的基因/蛋白质,即导致大脑产生不良反应的机制。与神经发育障碍相关的毒遗传学研究(汞)或非常稀缺(铅)。因此,重金属相关神经发育结果的易感性变异程度描述得很差。